Cargando…
BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations
The bromodomain and extra-terminal (BET) proteins act as “readers” for lysine acetylation and facilitate the recruitment of transcriptional elongation complexes. BET protein is associated with transcriptional elongation of genes such as c-MYC and BCL-2, and is involved in the regulation of cell cycl...
Autores principales: | Ma, Tao, Chen, Yan, Yi, Zhi-Gang, Li, Yan-Hong, Bai, Jun, Li, Li-Juan, Zhang, Lian-Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chongqing Medical University
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404881/ https://www.ncbi.nlm.nih.gov/pubmed/37554207 http://dx.doi.org/10.1016/j.gendis.2022.03.004 |
Ejemplares similares
-
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
por: Abedin, Sameem M, et al.
Publicado: (2016) -
The BET family in immunity and disease
por: Wang, Nian, et al.
Publicado: (2021) -
To Bet or Not to Bet on T-bet As a Therapeutic Target in Emphysema?
por: Wang, Xiaoyun, et al.
Publicado: (2019) -
BETting on combination to overcome PARPi resistance
por: Zhang, Youyou, et al.
Publicado: (2017) -
BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
por: Wang, Huijin, et al.
Publicado: (2022)